Based on the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epithelial growth factor receptor 2 (HER2), BCs are clinically categorised into three major groups: ER+, HER2+ and triple negative breast cancer (TNBC).1 This evidence concerns the gene PGR and triple-negative breast carcinoma.